Have a feature idea you'd love to see implemented? Let us know!

ORKA Oruka Therapeutics Inc.

Price (delayed)

$28.46

Market cap

$34.41M

P/E Ratio

N/A

Dividend/share

$19.36

EPS

-$6

Enterprise value

$1.12M

Highlights
The company's debt has shrunk by 100% YoY
The company's quick ratio rose by 15% QoQ and by 4.5% YoY
Oruka Therapeutics's net income has decreased by 20% QoQ and by 14% YoY
Oruka Therapeutics's EPS has decreased by 19% from the previous quarter and by 16% YoY

Key stats

What are the main financial stats of ORKA
Market
Shares outstanding
1.21M
Market cap
$34.41M
Enterprise value
$1.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$7.2M
EBITDA
-$7.12M
Free cash flow
-$6.89M
Per share
EPS
-$6
Free cash flow per share
-$5.7
Book value per share
$26.94
Revenue per share
$0
TBVPS
$28
Balance sheet
Total assets
$33.84M
Total liabilities
$1.27M
Debt
$0
Equity
$32.57M
Working capital
$32.55M
Liquidity
Debt to equity
0
Current ratio
26.61
Quick ratio
26.19
Net debt/EBITDA
4.68
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-19.5%
Return on equity
-20.2%
Return on invested capital
N/A
Return on capital employed
-22.1%
Return on sales
N/A
Dividend
Dividend yield
68.01%
DPS
$19.36
Payout ratio
N/A

ORKA stock price

How has the Oruka Therapeutics stock price performed over time
Intraday
3.45%
1 week
13.84%
1 month
1.64%
1 year
16.26%
YTD
39.51%
QTD
16.12%

Financial performance

How have Oruka Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.13M
Net income
-$7.2M
Gross margin
N/A
Net margin
N/A
Oruka Therapeutics's net income has decreased by 20% QoQ and by 14% YoY
ORKA's operating income is down by 16% year-on-year and by 14% since the previous quarter

Growth

What is Oruka Therapeutics's growth rate over time

Valuation

What is Oruka Therapeutics stock price valuation
P/E
N/A
P/B
1.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Oruka Therapeutics's EPS has decreased by 19% from the previous quarter and by 16% YoY
ORKA's price to book (P/B) is 28% higher than its 5-year quarterly average of 0.8 and 2% higher than its last 4 quarters average of 1.0
The company's equity fell by 17% YoY and by 7% QoQ

Efficiency

How efficient is Oruka Therapeutics business performance
Oruka Therapeutics's return on assets has decreased by 32% YoY and by 26% QoQ
The return on equity has declined by 31% year-on-year and by 25% since the previous quarter

Dividends

What is ORKA's dividend history
DPS
$19.36
Dividend yield
68.01%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Oruka Therapeutics financials performed over time
Oruka Therapeutics's total liabilities has decreased by 31% YoY and by 20% QoQ
The company's total assets fell by 18% YoY and by 8% QoQ
The company's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% YoY
The company's debt has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.